NCT07235748 2026-02-17
Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants
Servier
Phase 1 Completed
Clinical Trials
6 trialsNCT04530981 2024-09-19
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT04718740 2023-08-14
A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT03028103 2023-06-26
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
Ipsen
Phase 1 Completed
NCT04457180 2022-10-26
A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Completed
NCT02475499 2016-03-14
Incretin-based Drugs and Pancreatic Cancer
Canadian Network for Observational Drug Effect Studies, CNODES
Completed